Clovis Oncology stock surges 50% on positive late-stage cancer trial results – MarketWatch


UtahHerald.com

Clovis Oncology stock surges 50% on positive late-stage cancer trial results
MarketWatch
Clovis Oncology Inc. CLVS, +0.45% shares surged 50% in premarket trade Monday after the company said its late-stage trial for a cancer drug met its primary endpoint and a key secondary endpoint. Clovis said it plans to try for Food and Drug ...
Clovis's ovarian cancer drug set for label expansion, shares soarNasdaq
Clovis Oncology's 45% Pre-Market Surge, ExplainedBenzinga
Clovis to settle class action lawsuit for $142M in cash and stockSeeking Alpha
StreetInsider.com -Investor's Business Daily -Endpoints News -Highlight Press
all 95 news articles »